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DILIDeveloping biomarkers for detecting acetaminophen (APAP) toxicity has beenwidely investigated. Recent stud-
ies of adults with APAP-induced liver injury have reported human serum microRNA-122 (miR-122) as a novel
biomarker of APAP-induced liver injury. The goal of this studywas to examine extracellularmicroRNAs (miRNAs)
as potential biomarkers for APAP liver injury in children. Global levels of serum and urine miRNAs were exam-
ined in three pediatric subgroups: 1) healthy children (n = 10), 2) hospitalized children receiving therapeutic
doses of APAP (n = 10) and 3) children hospitalized for APAP overdose (n = 8). Out of 147 miRNAs detected
in the APAP overdose group, eight showed signiﬁcantly increased median levels in serum (miR-122, -375,
-423-5p, -30d-5p, -125b-5p, -4732-5p, -204-5p, and -574-3p), compared to the other groups. Analysis of urine
samples from the same patients had signiﬁcantly increased median levels of four miRNAs (miR-375, -940, -9-
3p and -302a) compared to the other groups. Importantly, correlation of peak serum APAP protein adduct levels
(an indicator of the oxidation of APAP to the reactivemetabolite N-acetyl-para-quinone imine)with peakmiRNA
levels showed that the highest correlation was observed for serum miR-122 (R = 0.94; p b 0.01) followed by
miR-375 (R = 0.70; p = 0.05). Conclusion: Our ﬁndings demonstrate that miRNAs are increased in children
with APAP toxicity and correlate with APAP protein adducts, suggesting a potential role as biomarkers of APAP
toxicity.
Published by Elsevier Inc.Introduction
Acetaminophen (APAP) is one of themost commonly used drugs for
pain and fever in adults and children (James et al., 2008; Algren, 2008).
The drug is generally considered to be safe when administered at doses
recommended by the manufacturer. However, APAP overdose is a very
common cause of acute liver failure (ALF) in adults, and accounts for
~14% of ALF in children (Squires et al., 2006). Since the etiology of ALFliver injury; APAP, acetamino-
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ck Lane, Sarasota, FL, USA.for up to 40% of pediatric cases is unknown, it is possible that undiag-
nosed APAP overdose is responsible for some of these indeterminate
ALF cases (James et al., 2008). While liver injury itself is detected by
increases in serum transaminase and bilirubin, the current approach
for diagnosing APAP poisoning relies on a history of APAP exposure
and quantitation of APAP in peripheral blood within the ﬁrst 24 h
after the overdose (i.e., the Rumack nomogram). Limitations of this
approach have been well-described and more sensitive, mechanism-
based biomarkers are needed (McGill et al., 2012, 2014a, 2014b). Early
biomarkers, which correctly identify individuals with toxicity, could
be important to detect patients at risk for developing ALF.
MicroRNAs (miRNAs) show promise as possible new biomarkers of
disease and injury (Chen et al., 2008). miRNAs are typically 21–23 nu-
cleotides long and regulate gene expression by binding to the 3′
untranslated regions (3′UTR) of their target mRNAs (Ambros, 2004;
Krol et al., 2010). Since miRNAs can be detected in body ﬂuids, they
are appealing as noninvasive biomarker candidates (Etheridge et al.,
2011). Our laboratory previously reported that urinary miRNA pro-
ﬁles were altered in rats after administration of hepatotoxic doses of
acetaminophen or carbon tetrachloride (Yang et al., 2012a). Studies in
the mouse model of APAP toxicity found that miR-122 and miR-192,
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markers (Wang et al., 2009). Compared to alanine aminotransferase
(ALT), miR-122 is liver speciﬁc and represents over 70% of the total
livermiRNAs (Chang et al., 2004). Recent clinical studies support the in-
crease of serummiR-122 under conditions of hepatotoxicity in patients
with APAP overdose (Antoine et al., 2013; Starkey Lewis et al., 2011,
2012; Thulin et al., 2013; Krauskopf et al., 2014). Elevations of miR-
122 have also been reported in heparin-induced liver necrosis (Harrill
et al., 2012), liver steatosis (Cermelli et al., 2011) and hepatitis B and C
infections (Su et al., 2013; Arataki et al., 2013; Laterza et al., 2013). It
is important to note that these studies did not address the usefulness
of measuring serum miR-122 levels in children exposed to high doses
of APAP.
In this investigation, globalmiRNA levelswere examined using small
RNA sequencing of serum samples and human miRNA PCR array analy-
sis on urine samples from three pediatric subgroups. The subgroups
were 1) children with no recent APAP exposure, 2) hospitalized chil-
dren receiving APAP for treatment of pain and fever, and 3) children
with APAP overdose. We evaluated the hypothesis that miRNA expres-
sion proﬁlesmay have diagnostic potential for APAP toxicity in children.
Method
Study population and design. The study was approved by the institu-
tional review board of the University of Arkansas for Medical Sciences.
Following informed consent and assent when age appropriate, blood
and urine samples were collected from study subjects (n = 28). There
were three subject groups: 1) control group, deﬁned as healthy children
with no use of APAP in the preceding 14 days (N = 10); 2) APAP ther-
apeutic group, deﬁned as hospitalized children receiving APAP per stan-
dard of care (N=10); and 3) APAP overdose group, deﬁned as children
requiring hospitalization for treatment of APAP overdose (N= 8). Clin-
ical information on study subjects included gender, weight, and dose or
doses of APAP received (Group 2) or ingested (Group 3), reported as
mg/kg. A single sample was collected in Groups 1 and 2, while multiple
samples were collected from some patients in Group 3. Blood samples
were centrifuged immediately after collection, and serum and urine
samples were stored at−80 °C until further analysis.
Serum ALT and APAP protein adducts quantiﬁcation. Serum ALT levels
were quantiﬁed in the clinical laboratory of Arkansas Children's Hospi-
tal. Serum APAP protein adduct levels were quantiﬁed through a high-
performance liquid chromatography with electrochemical detection
assay as previously described (Muldrew et al., 2002; James et al., 2003,
2009).
Serum and urine miRNA proﬁling. Total RNA was isolated from serum
(50 μl) using the method described previously (Yang et al., 2012a). The
serummiRNA (minimum of 300 ng total RNA) proﬁling was conducted
by Illumina high-throughput small RNA sequencing (HiSeq 2000,
Illumina), according to the manufacturer's protocol. Four samples
were not included in the analysis due to low RNA volume; therefore, a
total of 36 serum RNA samples were sequenced, including: 1) control
group, 9 samples from 9 subjects; 2) APAP therapeutic group, 8 samples
from 8 subjects; and 3) APAP overdose group, 19 samples from 8 sub-
jects. The Upper Quartile normalization method was used for data anal-
ysis (Bullard et al., 2010; Dillies et al., 2013), where the counts were
divided by the upper quartile of counts associated with their lane and
multiplied by the mean upper quartile of counts across all the samples
of the dataset. Absolute fold changes of N2-fold at p b 0.05 were consid-
ered signiﬁcant.
Total RNA was isolated from urine (300 μl) by the TRIzol method
(Yang et al., 2012a), and 300 ng of RNA was used to generate cDNA.
Whole genome proﬁling of urinary RNA samples was performed using
human miRNome miRNA PCR arrays (MAH-3200E, Qiagen, Frederick,
MD) covering 752 human miRNAs. These PCR arrays were run per themanufacturer's protocol (Qiagen) on a 7900 real-time PCR system
(Applied Biosystems Inc., Foster, CA). Relative miRNA expression levels
were determined with the ΔCt method per the manufacturer's recom-
mendations. Three miRNAs (miR-7, miR-671-3p, and miR-943), show-
ing low standard deviation, were selected to normalize the 752
miRNAs from PCR array. Fold changes of N2-fold at p b 0.05 were used
to select the signiﬁcantly altered miRNAs. Hierarchical unsupervised
clustering analysis (Heatmap) was performed as described previously
(Fang et al., 2009); normalized counts (serum) or ΔCt values (urine)
were used for these analyses.
Quantitative PCR validation. To validate the miRNA proﬁling results,
TaqMan miRNA qRT-PCR assay (Applied Biosystems) was performed on
selected miRNAs (miR-122 and miR-375) for the serum and urine sam-
ples and miR-940 levels were conﬁrmed by SYBR Green Qiagen kit as
the TaqMan assay was not available. This analysis was limited tomiRNAs
with a signiﬁcant correlation (p b 0.05) with APAP protein adducts.
Non-humanmiRNA, ath-miR159a (Arabidopsis thaliana), was spiked
into RNA samples as a control for extraction and ampliﬁcation steps.
Let-7d was used for normalization of serum samples based on the pre-
vious publication (Antoine et al., 2013) and miR-671-3p was used for
normalization of urine samples which was the most consistent urinary
miRNA.
Statistical analysis. A non-parametric method (Kruskal–Wallis one-
way analysis of variance by ranks) was used to determine whether
there was a signiﬁcant difference among the three subgroups. Dunn's
method was used for all pairwise multiple comparisons. For correlation
analysis between peakmiRNA and peak APAP protein adduct, Pearson's
correlation test was performed in SigmaPlot (version 11.0, Systat Soft-
ware Inc.), with p b 0.05 considered as statistically signiﬁcant.
Results
Elevations of ALT and APAP protein adducts
Serum ALT and APAP protein adduct values are summarized in
Table 1. Children in Groups 2 and 3 were older than those in Group 1.
The median unit dose of APAP in the therapeutic group was
12.6 mg/kg (range: 10–17.5 mg/kg) and the median daily dose was
17 mg/kg (range: 10.2–28.5 mg/kg). The median reported total APAP
exposure in overdose patients was 198.4 mg/kg (range: 58.6–
559.4mg/kg).Median values of ALT and APAP adductswere signiﬁcant-
ly (p b 0.05) higher in Group 3 than in the other groups.
Global serum and urine miRNA analysis
Small RNA sequencing (HiSeq 2000, Illumina) detected and quanti-
ﬁed a total of 147 miRNAs in all serum samples (n = 36). Comparison
of the subgroups revealed that eight serum miRNAs (miR-122, -375,
-423-5p, -30d-5p, -125b-5p, -4732-5p, -204-5p, and -574-3p) were in-
creased more than 2-fold in samples from the APAP overdose group
(Group 3) compared to the other subgroups (Table 2). Urinary miRNA
proﬁling using the whole genome PCR array found that miR-375, miR-
940, miR-9-3p andmiR-302awere increased in Group 3 (Table 3) com-
pared to the other two groups.miR-375was increased in both urine and
serum samples inGroup 3patients (Tables 2 and 3).WhilemiR-122was
detected in urine, it was not statistically different among the groups
(data not shown). To explore relationships between groups, hierarchi-
cal cluster analysis (HCA) was performed on the miRNA levels in indi-
vidual samples. Since repeated measures were available for the Group
3 subjects (at multiple time points during the hospitalization), only
the peak values were selected for HCA analysis. As shown in Fig. 1A,
levels of serum miRNAs could separate Group 3 (elevated ALT) from
Groups 1 and 2 (normal to low ALT). This panel included eight up-
regulated miRNAs (Table 2) and three down-regulated miRNAs (miR-
Table 1
Clinical and laboratory data of study subjects by group.
Age Gender
(male:female)
APAP dose
(mg/kg)
ALT
(IU/l)
APAP protein adducts
(nmol/ml)
1 Healthy control group (N = 10) 10.5 2:8 0 18 0.01
(5–15) (10–37) (0–0.01)
2 APAP therapeutic group (N = 10) 13.5 7:3 12.6 25 0.09
(5–18) (10.0–17.5) (6–177) (0.01–0.56)
3 APAP overdose group (N = 8) 16.0 5:3 198.4⁎ 1835⁎ 0.61⁎
(14–17) (58.6–559.4) (29–9909) (0.10–6.69)
Note: Data presented as median (range).
⁎ p b 0.05 by three way comparison.
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Similarly, a panel of 4 urinary miRNA (Table 3) partitioned the subjects
into two clusters: Group 3 (elevated ALT) vs. Groups 1 and 2 (Fig. 1B).
The variability within Group 3 may be secondary to differences in the
severity of or temporal stage of toxicity within this group, as was ob-
served with the ALT and APAP protein adduct measurements.
Comparison of miRNAs to toxicology parameters
To further examine the relationship between miRNAs and toxicity,
correlation analysis was performed among levels of APAP protein ad-
ducts, ALT and miRNAs in Group 3. Given that multiple measures
were available from each patient, the peak APAP protein adducts or
ALT values were used to examine the relationship of these parameters
to peakmiRNA levels. As shown in Fig. 2, there was a strong correlation
between serum miR-122 and APAP protein adducts (R = 0.94,
p b 0.001), whereas serum levels of miR-375 and APAP protein adducts
were moderately correlated (R = 0.70, p = 0.05). Urinary levels of
miRNAs (miR-940 andmiR-375)were not correlatedwith APAP protein
adduct levels or ALT. Interestingly, correlations between peak serum
miRNA levels and ALT values were not signiﬁcant (x symbol in Fig. 2,
R=0.69, p = 0.06 for miR-122), In addition, APAP dose was not corre-
lated with miRNAs, ALT or APAP protein adducts (data not shown).
Individual miRNA conﬁrmation
To conﬁrm the expression of miRNAs in body ﬂuids as biomarkers
for APAP-induced liver injury in children, qRT-PCR was performed on
individual miRNAs (serum miR-122/miR-375 and urine miR-940/miR-
375) which were correlated with APAP protein adducts (Fig. 2). AsTable 2
Distribution of serummiRNAs in study groups.
miRNA ID 1 Control 2 APAP therapeutic 3 APAP overdose
miR-122 0 0 96.5
(0–459.6) (0–243.6) (0–422.9)
miR-375 420.9 120.3 927.3b
(0–698.0) (0–1883.7) (349.3–8349.7)
miR-423-5p 15,785.7 6573.6 45,282.7a,b
(5833.3–29,882.2) (5691.1–25,723.4) (29,045.0–66,053.5)
miR-30d-5p 0 661.7 1829.5a
(0–507.6) (165.2–1404.6) (525.1–2701.4)
miR-125b-5p 0 0 110.0
(0–65.2) (0–79.5) (0–446.4)
miR-4732-5p 0 0 61.0a
(0) (0–66.1) (0–238.7)
miR-204-5p 0 0 46.6a
(0) (0–24.1) (0–69.9)
miR-574-3p 0 0 63.3
(0) (0–31.6) (0–358.0)
Note: miRNA levels are expressed as counts by NGS platform and presented as median
(range). For Dunn's pairwise comparison: a, p b 0.05 for Group 3 vs 1; b, p b 0.05 for
Group 3 vs 2. Eight serum miRNAs (miR-122, miR-375, miR-423-5p, miR-30d-5p, miR-
125b-5p, miR-4732-5p, miR-204-5p, and miR-574-3p) were increased in Group 3
(ANOVA, p b 0.05).shown in Fig. 3A, serum miR-122 showed signiﬁcantly higher levels in
Group 3 (p b 0.01) compared to other groups (Groups 1 and 2).
Serum miR-375 (Fig. 3B) levels were also higher in Group 3 compared
to other groups (p b 0.05); however, the separation was not as good
as that for miR-122. Urinary expression levels of miR-940 and miR-
375 were signiﬁcantly increased in Group 3 compared to Groups 1
and 2 (Figs. 3C–D).Time course of miRNA, ALT and APAP protein adduct alterations
To further characterize the temporal changes of these miRNAs in
body ﬂuids, and compare them to those of established biomarkers
(e.g., ALT), HCA was carried out on subjects with multiple time points.
In Fig. 4, each subject was assigned a unique letter of the alphabet (A–
H) and each sample identiﬁed by the day after APAP ingestion (days
2–7). The elevation of miR-122 was similar to APAP adduct and ALT,
which had peaked at day 4, in subjects B and C (bottom of the cluster).
However, miR-375 and other miRNAs peaked earlier, at day 3 (subjects
A, B, E). Among the8 subjects in the overdose group, selected individuals
with at least 3 time course data are presented (serum: Figs. 5A–C; urine:
Figs. 5D–F). The time course data covers the progression, peak and re-
solving toxicity. Interestingly, for subject 2 (Fig. 5B and Supplementary
Fig. 1) which displayed a mild ALT increase (peak value less than
1000 IU/l), the level of serum miR-122 increased earlier and returned
to baseline earlier than that of ALT. The levels of urinary miR-375 also
showed temporal changes, with peaks coinciding with that of ALT
changes for two of the three subjects. For subject 1 (Figs. 5A and D),
for both serum and urine time course data, levels of urinary miR-375
both increased and returned to baseline at earlier times compared to
those of serum miR-122 and ALT.
To further examine the relationship of the miRNAs to time course
data, the time to reach peak measurement for each miRNA was com-
pared to, APAP protein adducts and ALT. As shown in Fig. 6, it appears
that overall, these biomarkers, either from serum or urine, reached
peak values in a similar range of time (92–110h) as ALT or APAP protein
adducts.Table 3
Distribution of urinary miRNAs in study groups.
miRNA ID 1 Control 2 APAP therapeutic 3 APAP overdose
miR-940 35.2 25.3 104.1b
(9.4–97.3) (5.4–63.7) (19.9–634.4)
miR-375 3.1 2.0 10.7b
(0.2–16.0) (0.2–6.2) (0.8–50.0)
miR-302a 1.3 0.8 17.8a,b
(0.2–117.6) (0.2–1.6) (1.7–295.5)
miR-9-3p 135.3 436.2 1186.3a
(55.3–474.8) (96.7–834.5) (133.3–4371.2)
Note: The relative miRNA levels are expressed as relative concentration, normalized to
three endogenous miRNAs (miR-7, miR-671-3p, and miR-943), and presented as median
(range). For Dunn's pairwise comparison: a, p b 0.05 for Group 3 vs 1; b, p b 0.05 for Group
3 vs 2. One altered miRNA (miR-375) overlapped between serum and urine samples.
Fig. 1.Clustering analysis of study subjects based on thepattern of alteredmiRNAs, theAPAPoverdose group is separatedwith others. A.Heatmap analysis showing normalized counts and
a distinct serummiRNA pattern of the APAP overdose group. Group 1 (n=9) is indicated in green, Group 2 (n=8) is in orange and samples fromGroup 3 (n=8) are in red. B. Heat map
analysis showing normalized miRNA levels and a distinct urinary miRNA pattern of the APAP overdose group. Group 1 (n = 9) is indicated in green, Group 2 (n = 10) is in orange and
samples from Group 3 (n = 8) are in red.
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The advancement of high-throughput, large-scale technologies, such
as next generation deep sequencing, has signiﬁcantly expanded the
ﬁeld of biomarker research.With the discovery of stablemiRNAs in var-
ious body ﬂuids, increasing attention has been paid to the use of extra-
cellular miRNAs as potential biomarkers for informing early diagnosis,
choice of treatment and monitoring of disease progression or recovery
(Etheridge et al., 2011; Weber et al., 2010; Salminen et al., 2011). A
time course study in the mouse model of APAP hepatotoxicity showed
that the level of many plasma miRNAs inversely correlated with the
level of hepaticmiRNAs, indicating that for thesemiRNAs, hepatic injury
caused the release of miRNAs into the circulation system (Wang et al.,
2009). Recent studies in adults conﬁrmed the increase of serum miR-
122 in patients with APAP poisoning (Antoine et al., 2013; Starkey
Lewis et al., 2011, 2012; Thulin et al., 2013). However, serum miR-122
is not speciﬁc to APAP-induced liver injury and can be observed with
other causes of drug induced liver injury (Harrill et al., 2012) and viral
infection (Arataki et al., 2013; Ji et al., 2009). The hypothesis of this
study was that a panel of extracellular miRNAs can be used as bio-
markers to indicate APAP overdose in children and separate patientsexposed to therapeutic dose vs. overdose situations. To our knowledge,
this is the ﬁrst attempt to use small RNA sequencing for global miRNA
proﬁling to discover extracellular miRNA-based biomarkers for APAP
overdose in the pediatric population.
Using small RNA sequencing, up to 147 serummiRNAs exhibited al-
tered levels and 8 miRNAs were signiﬁcantly increased in children with
APAP overdose (Table 2). Serum miRNA proﬁles in Group 3 were dis-
tinct when compared to the other groups (Groups 1 and 2) (Fig. 1). Fur-
thermore, two serum miRNAs, miR-122 and miR-375, were strongly
correlated with peak serum APAP protein adducts. As expected, serum
miR-122 levels were signiﬁcantly elevated in APAP overdose patients
with almost undetectable levels in Groups 1 and 2 (Table 2). For urine
samples, a panel of 4 increased miRNAs (miR-375, miR-940, miR-9-3p
and miR-302a) was identiﬁed in the APAP overdose group. Interesting-
ly, miR-375 was elevated in both serum and urine samples in Group 3.
In adults, previous studies found that miR-122 increased earlier
(Thulin et al., 2013) and returned to baseline while ALT remained high
(Starkey Lewis et al., 2011, 2012). These previous observations suggest
that extracellular miRNA has a shorter half-life and will provide earlier
and possibly more accurate indication of APAP-induced liver injury.
Interestingly, the clustering analysis suggested that the changes of
Fig. 2. Correlation of peakmiRNA to APAP protein adducts or ALT, with p≤ 0.05was considered as statistically signiﬁcant. Correlation betweenmiRNAs (x-axis) and APAP protein adducts
(dot, left y-axis) or ALT levels (x-symbol, right y-axis) were determined by the Pearson's method: serum miR-122 (A), serum miR-375 (B), urine miR-940 (C) and miR-375 (D).
184 X. Yang et al. / Toxicology and Applied Pharmacology 284 (2015) 180–187miR-122 followed the rise in ALT and APAP protein adducts, while other
miRNAs preceded (Fig. 4). These divergent ﬁndings for miR-122 time
course changes could be explained by the heterogeneity of the patients
and the variance in the timing of sample collection. Therefore, addition-
al studies in wider cohorts of APAP-induced liver injury should be con-
ducted to test miRNAs' prognostic value.
Human studies of miRNAs in APAP toxicity have primarily focused
on miR-122 (Starkey Lewis et al., 2011). Other liver-rich miRNAs, such
as miRNA-125b-5p and miR-192-5p have been reported to increase in
APAP-treated mice (Bala et al., 2012). In this study, a signiﬁcant eleva-
tion of miR-192-5p was noted in the APAP therapeutic group. Our cur-
rent study found several miRNAs that have not been reported before:
miR-375 andmiR-940. The function of miR-940 is still unclear. Interest-
ingly, miR-375 has previously been associated with pancreatic diseases
(El Ouaamari et al., 2008), lung development (Wang et al., 2013), breast
and gastric cancer (de Souza Rocha Simonini et al., 2010; Ding et al.,
2010). The gene targets of miR-375 play important roles in insulin se-
cretion (Poy et al., 2004) and cell proliferation (Wang et al., 2013). It
is likely that miRNAs discovered in this study interact with key mole-
cules in cell death and proliferation; therefore, it is not surprising to
see that some of the altered miRNAs have been reported to be associat-
ed with other human diseases. In addition, a recent study conducted in
adults with APAP hepatotoxicity suggested that the highest elevations
of circulatingmiRNAs did not come from liver tissue (Ward et al., 2014).
Urinary biomarkers may provide a more speciﬁc, sensitive and con-
sistent indicator of liver injury than existing biomarkers (Yang et al.,
2012a). One potential limitation of urinary miRNAs is that not all
serum miRNAs are excreted into the urine due to different “ﬁltering”
processes and urine has far fewer detectable miRNAs than other
human body ﬂuids (Weber et al., 2010). The main advantages of using
urinary biomarkers are that the sample collections are non-invasiveand multiple time-series measurements are easy to obtain (Yang et al.,
2012b). In addition, such samples can be collected in a relatively large
amount, which is a limitation for serum miRNA quantiﬁcation.
This study provides the ﬁrst published serum and urine miRNA
proﬁles for APAP poisoning in children. Importantly, this work serves
as a proof of concept that the alteration in extracellular miRNA could
be a useful biomarker to timely represent the hepatocellular injury.
One major limitation of our study is that a small number of subjects
were analyzed. This decreased the power of the study and larger studies
will be required to conﬁrm the ﬁndings. In addition, Group 3 included
samples collected at various time points after the APAP overdose;
whereas, a single time point was used for Groups 1 and 2. APAP over-
dose subjects present in multiple stages of APAP poisoning, such as:
1) before injury has occurred, 2) during the peak of toxicity and 3) dur-
ing the resolution of toxicity. Hence, there are diversemiRNA alteration
patternswithin Group 3 (Fig. 1B),which limited our ability to fully char-
acterize temporal patterns among biomarkers. The 4 urinary miRNAs
identiﬁed in the current study do not overlap with the previous rat
study (Yang et al., 2012a). A major difference is that all overdosed sub-
jects of our current study received N-acetyl-cysteine (NAC) treatment.
NAC is the standard-of-care treatment for APAP overdose; it serves as
a precursor for GSH synthesis and reduces oxidative stress. Thismay ex-
plain why a relatively small number of miRNAs were identiﬁed in the
current study compared to our previous rat study.
In summary, this study identiﬁed altered miRNA patterns in serum
andurine fromchildren,which are potential biomarkers of APAP toxicity.
Furthermore, the elevation of serummiR-122 in the pediatric population
is similar to that reported for adults with APAP poisoning. The data here-
in suggest that multiple serum miRNAs associate with liver injury, but
the most notable appear to be miR-122 and miR-375 as they exhibited
a high correlation with the level of serum APAP protein adducts. Urinary
Fig. 3. Increases of miRNAs from APAP overdose children conﬁrmed by qRT-PCR. SerummiRNA levels, miR-122 (A) and miR-375 (B), from each group were reported as relative miRNA
concentration, with the formula 2^−ΔCt normalizedwith Let-7d. Urinary miR-940 (C) and miR-375 (D) levels from each groupwere reported as relative concentration normalizedwith
miR-671-3p. APAP overdose subgroup shows a signiﬁcant median increase in the miRNA levels (* p b 0.05, ** p b 0.01).
Fig. 4. Clustering analysis of ALT, APAP adducts and miRNAs peak time from overdose subjects with multiple measures. Overdose subjects were listed by alphabet (A–H) and days after
APAP ingestion (days 2–7). For example, B_4 is sample collected from subject B at day 4 after APAP overdose. HCA analysis showingmiR-122 peaks at similar time as ALT or APAP protein
adducts, however, some miRNA levels precede those of ALT or APAP protein adducts.
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Fig. 5. Time courses ofmiRNAs and ALT in selected APAP overdose children.Multiple sampleswere collected fromGroup 3 subjects, and the hours after APAP ingestionwere recorded. The
time course data covers different stages of toxicity: before or during the injury (before peak values) or during the resolution of toxicity (after peak). (A–C) Time course changes of serum
miR-122 from individual APAP overdose child (n = 3); (D–F) time course changes of urinary miR-375 from individual APAP overdose child (n = 3).
186 X. Yang et al. / Toxicology and Applied Pharmacology 284 (2015) 180–187miR-940 and miR-375 were also elevated in subjects overdosed with
APAP. In addition, the time course analyses provide a basis for future
studies to validate miRNA as useful prognostic biomarkers in clinical set-
ting. Qualifying these results on a larger cohort may provide stable and
sensitive miRNA biomarkers of hepatotoxicity. Additional studies of
liver injury not caused by APAP will be required to determine the bio-
markers' speciﬁcity for APAP-mediate liver injury. In summary, this
study identiﬁedmultiplemiRNAs in serum and urine that are potentially
altered by APAP exposure which may prove useful as APAP-speciﬁc bio-
markers or, more likely, biomarkers of liver injury in general.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2015.02.013.Fig. 6. Comparison of time to reach peak APAP protein adducts, ALT and miRNAs. Time to
reach peak measure for each miRNA was compared to known hepatotoxicity biomarkers
(APAP protein adduct and ALT). The peak times were similar, with median in the range
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